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2ABSTRACT ： We reported recently that berberine, a traditional oriental medicine to treat 
gastroenteritis, binds and activates Retinoid X receptor α (RXRα) to suppress the growth of colon 
cancer cells. Here, we extended our studies based on the binding mode of berberine with RXRα 
by design, synthesis and biological evaluation of a focused library of 15 novel berberine analogues. 
Among them, 3,9-dimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-12) 
was identified as the optimal RXRα activator. More efficiently than berberine, B-12 bound and 
altered the conformation of RXRα/LBD, thereby suppressing Wnt/β-catenin pathway and colon 
cancer cell growth via RXRα mediation. In addition, B-12 not only preserved berberine’s tumor 
selectivity but also greatly improved its bioavailability. Remarkably, in mice, B-12 did not show 
obvious side effects including hypertriglyceridemia as other RXRα agonists, or induce hepatorenal 
toxicity. Together, our study describes an approach for the rational design of berberine-derived 
RXRα activators as novel effective antineoplastic agents for colon cancer.
■ INTRODUCTION
Colon cancer is the third most common malignancy and the fourth leading cause of cancer-
related deaths worldwide. It is initiated in the epithelial cells lining the colon or rectum and 
frequently results from Wnt/β-catenin signaling pathway overactivation that is driven by mutations 
in pathway components, such as adenomatous polyposis coli (APC) and β-catenin.1 In the past two 
decades, the survival rate has increased significantly profiting from multiple new therapeutic 
methods. However, the 5-year disease-specific overall survival rate is still lower than 60% due to 
tumor recurrences and drug resistances.2, 3 New agents targeting important molecules in colon 
cancer development, with potent antitumor efficacy and low toxicity, is still urgently needed.
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3Retinoid X receptor α (RXRα), a unique member of the nuclear receptor superfamily, 
participates in a wide range of cellular processes under physiological and pathophysiological 
conditions through modulating gene expression in a ligand-dependent manner. The abnormal 
expression or post-translational modification of RXRα is closely related to the development of 
several types of cancers, such as colon cancer.4-6 Hyperphosphorylation of RXRα, resulting in its 
transactivation inhibition, was detected in a series of human colon cancer cell lines and primary 
human colon cancer tissues.7 RXRα expression was also downregulated in APC mutant mice.8 
Proteomics analyses demonstrated that more than 70% of the significantly down-regulated proteins 
are associated with abnormal RXRα signaling pathway in colon cancer tissues.9 Additionally, 
extensive crosstalk between RXRα and Wnt/β-catenin signaling pathway was also observed in 
colon cancer.10, 11 Suppression of RXRα and aberrant β-catenin expression significantly associate 
with progression of colon cancer.12, 13 RXRα agonists increased β-catenin and RXRα protein 
interaction, leading to the degradation of β-catenin and the inhibition of cell growth in colon 
cancer.14, 15 Therefore, RXRα is considered to be an important target for colon cancer treatment. 
Identifying and optimizing molecules that bind to its canonical ligand-binding pocket (LBP) has 
long been the focus of drug discovery efforts targeting RXR, and a large pool of such RXR 
ligands have been reported, such as 9-cis-retinoid acid (9-cis-RA), targretin (LGD1069) and 
sulindac.16, 17 However, there are key limitations of treatment with these ligands including 
unwanted side effects such as hypertriglyceridemia, mucosal toxicity, hypercalcemia, and 
hepatomegaly.4, 16-18 The current challenge is to discover selective RXR modulators with desired 
pharmacological activities and minimal undesired side effects.4, 16, 17
Berberine (Figure 1a), an isoquinoline alkaloid isolated from several Chinese herbs such as 
Coptis chinensis, is a nonprescription medicine traditionally used to treat gastroenteritis. In recent 
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4years, pharmacological and clinical studies have displayed a broad range of benefits from 
berberine treatment, including antidiabetic, antihyperlipidemic, and antitumor effects.19-22 In 
several cancer models, berberine has been proven to reduce cell proliferation, induce cell apoptosis 
and inhibit tumor angiogenesis and metastasis, which makes berberine a promising drug for cancer 
therapy.23, 24 Notably, berberine is a radiosensitizer of tumor cells but not normal, untransformed 
cells, and also displays high selectivity for colon cancer cells relative to normal colon epithelial 
cells.25 Our recent study demonstrated that berberine acted as a novel RXRα activator to suppress 
β-catenin signaling and cell growth in colon cancer through directly binding to a unique site (Site 
X) on the ligand-binding domain (LBD) of RXRα, which is likely the main reason for the tumor 
selectivity of berberine and thus provided new strategies for the design of new RXRα-based 
antitumor agents.26 However, some limitations of berberine, including poor solubility, low 
bioavailability, and moderate tumor-suppressing activity,27, 28 restrict its clinical application to 
treat colon cancer. Structural modification of berberine would be an effective way to solve this 
dilemma. Some modifications of berberine have been carried out trying to improve its bioactivity 
and bioavailability in antimicrobial, antidiabetic, antihyperlipidemic and antitumor effects. 
Modification at C8 and C13 greatly increased the antimicrobial activity of berberine, which is 
closely related to the substituent chain length.29-31 Most of the berberine derivatives with halogen 
and heteroaromatics on C8, C9 position displayed stronger hypoglycemic ability than berberine.32, 
33 Structure-activity studies on the antitumor effect of berberine mainly focused on the C8, C9, and 
C13 positions; for example, 13-alkyl derivatives of berberine showed higher antitumor activities 
than berberine, and a moderate alkyl chain length was beneficial for its antitumor activity.34-36 
However, almost all these modifications are randomly made and effect-oriented, lacking a 
structural basis for the mechanism of berberine’s effects. Most of these derivatives, by inserting 
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5either a long aliphatic chain or a heterocyclic ring, may have significant effects but lose the 
biosafety of berberine since the structures were changed too much. Moreover, these derivatives 
were mostly accessed by modification of natural berberine, thus significantly restricting the 
structural diversity necessary for structure-activity relationship (SAR) studies.   
Our previous studies identified RXRα as an intracellular target of berberine to suppress colon 
cancer growth and disclosed a unique binding mode of berberine with RXRα,26 which provides an 
ideal theoretical base for SAR design of new anti-tumor berberine analogues. In the present study, 
based on our previous findings, we designed and prepared 15 berberine analogues (nine of them 
are new compounds) in a total synthesis manner with modifications on the C2/3/9/10/11/12 
positions of berberine, in an attempt to find a molecule possessing similar tumor-selectivity to that 
of berberine but with enhanced antitumor activity and bioavailability.
 ■ RESULTS
Design and synthesis of berberine analogues targeting RXRα
We described recently how berberine (Figure 1a) acts as an RXRα activator through direct 
binding to the Site X (non-classical ligand-binding pocket) in the ligand-binding domain (LBD) 
of RXRα to activate its transactivating function and its regulation on Wnt/β-catenin signaling to 
inhibit colon cancer growth; the C2, C3 groups on the head of berberine form H-bonds with the 
Arg371 residue of RXRα, and the C9, C10 methoxy groups on the tail region of berberine form 
Van Der Waals contacts with RXRα (Figure 1b).26 To obtain more efficient RXRα activator and 
overcome aforementioned drawbacks residing in berberine as a promising antineoplastic agent, we 
designed 15 berberine analogues with modifications on C2, 3, 9, 10, 11 and 12 positions based on 
Page 5 of 54
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6the mode of berberine binding to RXRα. The structures of these analogues were shown in Table 
1.
Figure 1. Chemical structure of berberine (a) and the binding site in RXRα-LBD (b)
(a) Chemical structure of berberine. Red arrows indicated the sites to be remodeled. (b) Detailed 
view of the interaction between berberine (yellow) and RXRα/LBD (cyan) (PDB:3FUG) in Site 
X. Key residues involved in berberine binding were shown in sticks; potential hydrogen-bonding 
interaction between berberine and RXRα-LBD residues Arg371 was shown as dashed red line.
The analogues of berberine were prepared according to Donohoe’s protocol37 and a general 
synthetic sequence was illustrated in Scheme 1. The acetophenone 3 could be synthesized from 
the substituted phenylacetic acids through reduction followed by the protection of the resulting 
alcohol as a pivalate and a regioselective Friedel-Crafts acylation reaction with Ac2O and ZnCl2. 
Aryl bromide 6 was prepared from the corresponding o-bromobenzaldehyde through acetal 
protection. Then in the presence of [(Amphos)2PdCl2] and Cs2CO3, the cross-coupling between 
acetophenone 3 and aryl bromide 6 delivered 7. Finally, the desired berberine analogue was formed 
by heating the mixture of compound 7 and NH4Cl in EtOH/H2O. Through this reaction sequence, 
15 berberine analogues, named B-1 to B-15, were synthesized smoothly (Figure 2b). Among them, 
Page 6 of 54
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7B-2 (pseudocoptisine),38 B-4 (pseudoberberine),39 B-5 (pseudopalmatine),40 and B-11 
(palmatine)41 are natural products and B-142 and B-942 are known berberine analogues. The 
structure and purity (above 95% pure) of all berberine analogues were confirmed by qNMR 
analysis techniques. Berberine and its 15 analogues were screened by PAINS-remover 
(http://www.cbligand.org/PAINS) to filter out potential false-positive molecules and all these 
analogues were proved to be PAIN-less. 
 Reagents and conditions: (a) BH3·HF (2.0 equiv), THF, 0 °C→rt; (b) PivCl (2.0 equiv), pyridine 
(2.0 equiv), CH2Cl2, 0 °C→rt; (c) ZnCl2 (5.0 equiv), Ac2O, 0 °C→rt; (d) ethylene glycol (5.0 
equiv), PTSA (0.1 equiv), HC(OEt)3 (3.0 equiv), toluene, 90 °C; (e) [(Amphos)2PdCl2] (5 mol%), 
Cs2CO3 (2.5 equiv), THF, 90 °C; (f) NH4Cl, EtOH/H2O (3:1), 90 °C then 110 °C.
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8Table 1. Structures of the berberine analogues
N
Cl
R3
R4
R5
R6
R1
R2
Compound R1 R2 R3 R4 R5 R6
B-1 OCH2O H H H H
B-2 OCH2O H OCH2O H
B-3 OCH3 H H OCH3 OCH3 H
B-4 OCH2O H OCH3 OCH3 H
B-5 OCH3 OCH3 H OCH3 OCH3 H
B-6 OCH3 OCH3 H H H H
B-7 OCH3 H H H H H
B-8 OCH3 H H OCH2O H
B-9 OCH2O H OCH3 H H
B-10 OCH3 H OCH3 OCH3 H H
B-11 OCH3 OCH3 OCH3 OCH3 H H
B-12 OCH3 H OCH3 H H H
B-13 OCH3 OCH3 OCH3 H H H
B-14 OCH3 OCH3 H H H OCH3
B-15 OCH2O H H H OCH3
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9Structure-activity analyses identified B-12 as the most effective RXRα activator among these 
berberine analogues
Figure 2. Structure-activity analyses identified B-12 as the most effective RXRα activator among 
these berberine analogues. (a-d) Close-up view of the berberine analogues binding to RXRα-LBP 
(PDB code 3FUG). Compounds B-1, B-3, B-9, and B-12 were shown in yellow; and compounds 
B-4, B-5, B-6 and Berberine (Ber) were indicated in gray. Key residues involved in RXRα 
binding were shown in sticks. Potential hydrogen-bonding interaction between berberine 
analogues and RXRα/LBD Arg371 was shown as a dashed red line. (e) KM12C cells were co-
transfected with pG5luc plasmid and pBIND-RXRα-LBD or its mutants. Twenty hours after 
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10
transfection, cells were treated with 50 μM berberine or B-12; then the activities of the reporter 
gene were determined by luciferase assays and the basal level was normalized to 1. (f) KM12C 
cells co-transfected with pBIND-RXRα/LBD and pG5luc were treated with berberine or its 
analogues at 50 μM for 15 h.
With these compounds in hand, we carried out SAR studies by evaluating binding affinity to 
RXRα through molecular docking studies and further by biological tests (Figure 2 and Table 2). 
Firstly, the docking calculations suggested that the compounds with 2,3-methylenedioxy group 
have much better binding conformation than that with 2,3-dimethoxy group. As shown in Figure 
2a, the C3-oxygen of B-1 formed two H-bonds with the backbone of Arg371 in RXRα/LBD, while 
B-6 could not form any effective interactions with the surrounding amino acid residues. We next 
found that the single C3 methoxy group of B-3 is also beneficial for the compound to bind RXRα-
LBD, while the C2 methoxy group in compound B-5 seemed to hamper the compound to enter the 
binding-pocket and form H-bond with Arg371 of RXRα by comparing B3 and B5 (Figure 2b), 
which might result from the larger steric hindrance induced by the coexistence of C2 and C3 
methoxy groups. Next, we investigated the roles of functional groups present on the C9/10/11/12 
positions (the tail) of berberine core when the compounds have the same head structure. By 
comparing B-4 with B-9, we found 10,11-dimethoxy groups seemed to impede the binding of the 
compounds with RXRα/LBD, because even though B-4 has a methylenedioxy group at C2-C3 
positions, which is more favorable for binding to RXR protein, it is still almost outside the pocket 
(Figure 2c). Similar docking results mentioned above were obtained when comparing B-14 and B-
15, B-12 and B-13, B-2 and B-4, respectively (Figure S1a-c). It is worth noting, when the heads 
of compounds bear C3 single methoxy or 2,3-methylenedioxy groups, some analogues with 
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11
substituents on the C9/10/11 positions of berberine, except the analogues with bismethoxy groups 
on C10 and C11 (B-3 and B-4), could well match the binding-pocket and form H-bonds with 
Arg371, such as B-2, B-8, B-9, B-10 and B-12 (Figure S1d).
For further verification, we ranked the binding potential of berberine analogues with 
RXRα/LBD through molecular docking by four indexes, including shape matching, H-bond 
energy, protein solvation, and small molecule solvation. As shown in Table 1, the five top-scoring 
compounds are B-12, B-8, B-9, B-10 and B-2, which is consistent with the above conformational 
analysis. Next, the physiological consequences of the interactions between these compounds and 
RXRα/LBD were validated by their abilities to transactivate RXRα (Figure 2f), as well as to inhibit 
colon cancer cell growth, which were illustrated as IC50 in Table 2. The dose-response curves of 
representative compounds (Ber, B-8, B-9, B-10, B-12), along with 9-cis-RA as positive control, 
were shown in Figure S1e. The above results illustrated that compounds with higher binding 
potential to RXRα as indicated in molecular docking analysis indeed had a stronger ability to 
stimulate the transactivation activities of RXRα/LBD and inhibit the growth of colon cancer cells, 
such as B-8, B-9, B-10 and B-12; reversely, those showing poor binding potential exhibited little 
effect on the RXRα-LBD transactivation activity and inhibition of colon cancer cell proliferation, 
including B-4, B-5, B-6, B-7, B-13, and B-14. Among all these compounds, B-12, as expected, 
exhibited the strongest transcriptional activation ability to RXRα and the greatest inhibitory effect 
on colon cancer cell growth (Figure 2f and Table 2). B-12 has the lowest IC50 value to KM12C 
cell growth (31.10 μM), which was much smaller than that of berberine (76.34 μM). Based on 
these results, we further explored the binding conformation of compound B-12, and the results 
indicated that compound B-12 manifested a better binding conformation with RXRα/LBD (Figure 
2d), and its H-bond lengths with Arg371 of RXRα (3.0 Å, 3.11 Å) was far shorter than that of 
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berberine (3.9 Å, 3.2 Å). Subsequent mutation analysis confirmed that Arg371 is essential for the 
binding of RXRα/LBD with both B-12 and berberine (Figure 2e). We further confirmed the 
superiority of B-12 to berberine on cancer cell growth and RXR-dependent transactivation in 
another two colon cancer cell lines HCT116 and SW620. Results showed that B-12 exhibited 
excellent IC50 values in the growth inhibition of HCT116 and SW620 cells (27.17 μM and 36.19 
μM, respectively), which were less than one-third of that of berberine (83.09 μM and 126.20 μM, 
respectively) (Figure S2a). B-12 also acted much better than berberine to suppress colon cancer 
cell growth indicated by EdU (5-Ethynyl-2’-deoxyuridine) assay and PCNA (proliferating cell 
nuclear antigen, a cell proliferation marker) expression level (Figure S2b-c), and to enhance the 
transactivation activity of endogenous RXRα on RXR DNA response element (RXRE) in KM12C, 
HCT116 and SW620 cells (Figure S2d).
Table 2. Berberine analogues’ molecular docking conformational analysis score sheet and 
their inhibitory effects (IC50) on KM12C cell proliferation
Compound
Total 
Score
Hydrogen 
Bond
Shape
Ligand 
Desolvation
Protein 
Desolvation
IC50
(μM)
B-1 5.42 -0.92 -11.68 1.03 6.15 79.70
B-2 5.60 -0.94 -13.55 1.37 7.39 57.18
B-3 5.38 -0.98 -12.35 0.65 7.30 83.50
B-4 4.84 -0.96 -8.45 1.28 6.68 467.00
B-5 4.64 -0.21 -10.67 0.76 6.13 ＞600
B-6 4.00 -0.49 -10.66 1.18 5.96 ＞600
B-7 5.39 -0.83 -11.47 0.60 6.30 128.80
B-8 5.90 -0.69 -13.36 1.17 6.97 46.37
B-9 5.81 -0.81 -12.52 0.71 6.82 52.69
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 B-10 5.77 -0.98 -13.39 1.04 7.35 37.88
B-11 3.78 -0.89 7.83 1.31 -11.58 393.00
B-12 6.01 -0.95 -13.39 0.90 7.09 31.10
B-13 3.59 -0.11 -10.90 1.06 6.35 166.00
B-14 3.94 -0.47 -9.10 0.97 3.97 270.00
B-15 4.88 -0.81 -11.56 1.35 6.14 118.40
Ber 5.53 -0.90 -13.24 1.37 7.39 76.34
Evaluation of B-12 binding ability with RXRα
Molecular docking and bio-activity analysis above picked B-12 out as the most distinguished 
activator of RXRα among these 15 newly-synthesized berberine analogues (Figure 2). Several 
biophysicochemical methods were then employed to examine the binding ability of B-12 with 
RXRα. Firstly, we determined the physical interaction between B-12 and RXRα/LBD by 
saturation transfer difference (STD)-NMR spectroscopy. As shown in Figure 3a, the 1H NMR 
spectra with and without B-12 were obtained, and most signals were observed in STD-NMR 
spectra showing that RXRα/LBD protein interacts with B-12. We then used fluorescence 
quenching analysis to evaluate the binding affinity of B-12 to RXRα/LBD. His-RXRα/LBD 
displayed maximal fluorescence at 332 nm (Figure 3b, left panel). When the concentration of B-
12 or berberine was increased from 0 to 30 μM, the fluorescence intensity of RXRα/LBD gradually 
decreased, without a significant shift of the maximum fluorescence emission wavelength (Figure 
3b, left panel). Plotting of the data yielded titration curves (Figure 3b, right panel), from which the 
apparent dissociation constants (Kd) value was calculated as 1.89×10-5 M and 2.48×10-5 M for B-
12 and berberine binding to RXRα/LBD proteins, respectively. Finally, CD spectroscopic assay 
was performed to test whether B-12 could induce a change in the conformation of His-RXRα/LBD. 
The far-UV CD spectrum of His-RXRα/LBD exhibited two negative peaks at 208 nm and 222 nm 
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and a positive peak at 192 nm, suggesting the presence of α-helical structure (Figure 3c). Upon B-
12 binding, this conformation of His-RXRα/LBD was significantly changed, to a greater extent 
than that induced by berberine (Figure 3c). These results indicated that B-12 directly interacted 
with RXRα/LBD and altered its conformation, and the binding affinity of B-12 with RXRα/LBD 
was stronger than that of berberine.
Figure 3. B-12 directly bound to RXRα/LBD. (a) STD spectrum of B-12 and RXRα/LBD. The 
green spectra represented the 1H NMR spectra of B-12 alone. The red spectra represented the 1H 
NMR spectra of B-12 and RXRα incubated together. (b) Fluorescence quenching spectra (left) 
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15
and Stern-Volmer plot (right) for RXRα/LBD-berberine/B-12 interaction. (c) CD spectroscopic 
analysis of the binding of berberine and B-12 (5 μM) to RXRα/LBD (1 μM) with consequent 
conformational changes. 
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Figure 4. B-12 inhibited β-catenin signaling and cell proliferation in colon cancer cells. (a, b) 
Effects of berberine and B-12 on β-catenin signaling and β-catenin expression were respectively 
detected by TOP/FOP luciferase system and western blot. KM12C, HCT116, and SW620 cells 
were co-transfected with pRL-TK, TOPflash or FOPflash plasmids (for a). (c, d) Effect of 
berberine or B-12 on the binding ability of RXRα with β-catenin or and β-catenin with c-Cbl was 
detected by the mammalian two-hybrid assay. KM12C, HCT116, and SW620 cells were co-
transfected with pBIND-β-catenin/S33Y and pACT-RXRα (for c) or pBIND-β-catenin/S33Y and 
pACT-c-Cbl (for d) and then treated with berberine or B-12 for 15 h. (e, f) Western blot analyses 
and real-time PCR assays were performed to detect the protein/mRNA expression of Cdc2, c-Myc, 
and p21WAF1/CIP1 in KM12C, HCT116, and SW620 cells. Significant differences compared with 
the vehicle were indicated as **p<0.01 and ***p<0.001. Significant differences of B-12 vs Ber at 
the same dose were indicated as #p<0.05, ##p<0.01 and ###p<0.001.
B-12 inhibited β-catenin signaling and colon cancer cell growth via RXRα mediation
We reported recently that berberine suppressed colon cancer cell proliferation through binding 
to RXRα and promoting its interaction with nuclear β-catenin, leading to c-Cbl-mediated 
degradation of β-catenin.26 Therefore, we examined the effect of B-12 on Wnt/β-catenin signaling 
pathway in KM12C, HCT116, and SW620 colon cancer cell lines. B-12 inhibited β-catenin-
dependent transcriptional activity and induced degradation of β-catenin protein more obviously 
than berberine, as indicated by the TOP/FOP luciferase assay and western blot analysis (Figure 4a, 
b). Mammalian two-hybrid assay further demonstrated that the interaction of RXRα with β-catenin 
and β-catenin with c-Cbl was enhanced by B-12 more effectively than berberine (Figure 4c, d). In 
Page 16 of 54
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17
addition, the expression levels of Cdc2 and c-Myc, two target genes of the β-catenin signaling 
pathway involved in regulating the G2/M checkpoint,43 and p21WAF1/CIP1, a downstream effector 
of c-Myc for G2/M checkpoint regulation,44 were regulated by B-12 more significantly than 
berberine (Figure 4e, f). These results suggested that similar to berberine, B-12 also promotes 
RXRα–β-catenin interaction and inhibits β-catenin signaling and colon cancer cell growth, but its 
regulatory effect is much stronger than that of berberine.
We further investigated whether RXRα is essential for B-12 to suppress the hyperactivated β-
catenin signaling and cell growth in KM12C cells. We stably knocked down the expression of 
RXRα in KM12C cells with a specific shRNA against RXRα (Figure 5a). Silencing RXRα 
expression greatly reduced the ability of B-12 to inhibit cell growth, as detected by the MTT assay 
(Figure 5b). Our results also showed that the expression of β-catenin, Cdc2, c-Myc, and 
p21WAF1/CIP1 were regulated by B-12 in an RXRα-dependent manner (Figure 5c and Figure S3). 
These data suggested that RXRα mediated the inhibitory effect of B-12 on β-catenin signaling and 
cell growth in colon cancer cells.
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Figure 5. B-12 suppressed β-catenin signaling and cell proliferation in an RXRα-dependent 
manner. (a) KM12C cells were transfected with control shRNA or shRNA targeting RXRα, then 
the expression levels of endogenous RXRα were examined by western blotting analyses. (b, c) 
KM12C cells expressing control shRNA or shRNA targeting RXRα were treated with indicated 
concentrations of berberine or B-12 for 15 h, then the cell viability was measured by MTT assays 
(b) and the protein levels of Cdc2, c-Myc and p21WAF1/CIP1 were examined by western blot analysis 
(c).
B-12 inhibited tumor growth in vivo
We assessed the therapeutic effects of B-12 in a xenograft tumorigenesis model by 
subcutaneously injecting KM12C cells into nude mice. When the volume of xenografts had 
reached 80 to 200 mm3, the mice with similar tumor load were divided into three groups, and then 
respectively treated with vehicle, B-12 (100 mg/kg) and berberine (100 mg/kg), each day through 
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intragastric administration. Two weeks later, the tumors were dissected and weighed. Tumor 
growth was significantly reduced in B-12-treated and berberine-treated groups as compared to the 
vehicle group, and the inhibition rate was 69.1% (P < 0.01) and 33.6% (P < 0.05) for B-12 and 
berberine respectively (Figure 6a-c). B-12 also regulated the protein and mRNA expression of 
PCNA, Ki67, Cdc2, c-Myc, p21WAF1/CIP1 and β-catenin in the xenograft tumors, more effectively 
than berberine, as detected by western blot, real-time PCR and immunohistochemistry (Figure 6d-f 
and Figure S4, 5). These results indicated that B-12 inhibited colon cancer cell growth more 
efficiently than berberine in vivo.
Unwanted side effects, such as hypertriglyceridemia, mucosal toxicity, hypercalcemia and 
hepatomegaly, are the major obstacles of the clinical applications of current RXRα ligands. So we 
also tested the possible toxicity or side effects of B-12. Berberine and B-12 had no obvious 
hepatotoxicity and nephrotoxicity as indicated by the biochemical indexes of liver and renal 
function measured from the serum of mice after drug treatment (Table 3). The conclusion was 
further supported by the results from HE staining as no damaged hepatocellular morphology and 
augmented necrotic hepatocytes were observed (Figure 6g). The liver to body weight ratio also 
proved that berberine and B-12 did not cause hepatomegaly (Figure S6). Moreover, unlike the 
classical RXRα agonists, B-12 did not cause unwanted side effects such as hypertriglyceridemia, 
hypercalcemia and hypercholesterolemia (Table 3).
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Figure 6. B-12 inhibited tumor growth in mice. Mice xenografted with KM12C cells were treated 
with or without berberine or B-12 as described in the method. (a) Tumor volume was measured 
every 2 days. (b-c) Two weeks later, mice were sacrificed and the xenograft tumors were dissected 
and weighed. Representative images of tumors were shown in b. (d) Expression levels of β-catenin, 
Cdc2, c-Myc, and p21WAF1/CIP1 in xenografts were analyzed by western blot. (e, f) Representative 
images of the expression of β-catenin, Ki-67, Cdc2, c-Myc, PCNA and p21WAF1/CIP1 in xenograft 
tumors analyzed by immunohistochemistry. (g) Liver and kidney histopathology by HE staining.
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Table 3. Biochemical analyses of the serums from berberine or B-12 treated mice
Biochemical 
indexes
Vehicle
 (n=6)
Ber
(n=6)
B-12
(n=6)
P values
Ber VS 
Vehicle
P values
B12 VS Vehicle
TBIL (μmol/L) 0.28±0.024 0.26±0.032 0.21±0.029 0.4713 0.9617
IBIL (μmol/L) 0.55±0.096 0.40±0.057 0.52±0.083 0.8605 0.2423
ALT (U/L) 24.18±0.77 27.90±1.21 27.20±1.57 0.1635 0.2958
AST (U/L) 157.15±8.41 177.86±7.88 158.36±6.68 0.2239 0.9143
ALP (U/L) 76.53±4.31 71.28±3.16 78.35±5.99 0.8728 0.8739
CREA (μmol/L) 27.02±1.22 24.36±1.68 28.95±1.40 0.4813 0.6713
UREA 
(mmol/L)
8.21±0.26 8.08±0.62 8.39±0.41 0.8449 0.7600
Ca (mmol/L) 2.27±0.059 2.13±0.034 2.23±0.021 0.1413 0.9079
TG (mmol/L) 0.96±0.056 0.77±0.069 0.74±0.031 0.1241 0.0574
TC(mmol/L) 2.32±0.11 2.35±0.12 2.49±0.087 0.9908 0.9991
Data were presented as the mean ± SEM. Statistical significance is analyzed by one-way analysis 
of variance (ANOVA). P <0.05 was considered statistically significant.
Detection of tumor selectivity and bioavailability of B-12
Berberine has a significant advantage of high tumor selectivity (killing tumor cells but not 
normal cells), which makes it a promising anti-tumor drug. Therefore, we tested whether B-12 
could still retain this advantage of berberine, by detecting the cell viability in response to a series 
of concentrations of B-12 and berberine in human normal intestinal epithelial cell line HIEC-6 and 
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mouse fibroblast epithelial cell line MEF. Treatment with B-12 or berberine caused only a slight 
decrease in viability of HIEC-6 and MEF cells, suggesting that B-12 still preserved the high tumor 
selectivity of berberine (Figure 7a-b). Poor solubility and low bioavailability are two major 
weaknesses of berberine. Excitingly, the solubility of B-12 was increased to 10.66 times compared 
with berberine (Supplementary Table 1). The increasing solubility of B-12 is probably due to the 
decreasing intermolecular π, π-interaction caused by the more bulky C-3 methoxy group. We thus 
test whether the bioavailability of B-12 is also better than berberine. SD rats were treated with 
berberine (100 mg/kg) or B-12 (100 mg/kg) by gavage, then the blood was taken from the tail vein 
at different periods, and the drug concentration in the blood was detected by LC-MS. The results 
showed that both berberine and B-12 reached the maximum drug concentration at approximately 
2 hours, but the maximum drug concentration of B-12 was 167 times higher than that of berberine 
in the blood of rats (Figure 7c and Table 4). The results of the pharmacokinetic parameters of 
berberine and B-12 were shown in Table 4. Compared with berberine, the peak concentration 
(Cmax) was increased to 167.5 times; the area under the curve (AUC) was increased to 21.25 
times; the bioavailability (F%) of B-12 was raised to 26.10 times (Table 4), which might also 
contribute to B-12’s stronger in vivo inhibitory effect on tumor growth. These results indicate that 
B-12 not only reserves the high tumor selectivity of berberine but also greatly improves its 
bioavailability.
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Figure 7. Detection of tumor selectivity and bioavailability of B-12. (a, b) MEF and HIEC-6 cells 
were treated with berberine or B-12 for 15 h. The viability of cells was determined by MTT assay. 
(c) Berberine (100 mg/kg) or B-12 (100 mg/kg) were given to SD rats by intragastric 
administration, and plasma samples were collected at 0.038, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 and 36 
h for analyses of berberine and B-12 by LC-MS.
Table 4. The pharmacokinetic parameters of berberine 
and B-12 (PO 100mg/kg) 
Compound Ber B-12
T1/2 (h) 28.98 11.59
Tmax (h) 2.000 2.000
Cmax (ng/mL) 2.893 486.0
AUC0-t (ng·h/mL) 99.00 2104
MRTINF (h) 31.51 15.67
F% 0.544 14.20
■ DISCUSSION AND CONCLUSIONS
Many studies have identified RXRα as an important target for cancer therapy, especially in colon 
cancer.5, 45-48 We recently reported that berberine inhibits colon cancer cell growth through direct 
binding to a unique site (non-classical ligand-binding pocket) in RXRα/LBD to activate its 
transactivating function and its regulation on β-catenin pathway.26 To obtain more efficient 
berberine analogues as RXRα activators, which are very likely to retain the advantage of berberine, 
we designed and synthesized a series of novel berberine analogues with modifications on the C2, 
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3, 9, 10, 11 and 12 positions of berberine core based on its binding mode with RXRα (Figure 1-
2). By analyzing the structure-activity relationship of berberine analogues and RXRα, we 
identified B-12 as an effective analogue with stronger anticancer activity, comparative tumor 
selectivity, and significantly improved bioavailability, notably with no adverse side effects caused 
by traditional RXRα agonists, and no obvious toxicity to mice, which made it a promising 
therapeutic agent for colon cancer treatment. (Figure 2-7).
Through structure-bioactivity analysis, we have summarized the important relationships 
between the structural components of berberine analogues and their binding and activation of 
RXRα. First, the presence of particular groups on the C2, C3 positions (the head moiety) of 
berberine to form H-bonds with the Arg371 residue of RXRα may be required. Single C3 methoxy 
group or C2-C3 methylene-dioxy group can easily and closely interact with RXRα through 
formation of H-bonds with RXRα Arg371, and consequently exhibiting superior bio-activities in 
the activation of RXRα and the inhibition of colon cancer cell growth; moreover, single C3 
methoxy group is a little more favorable than the C2-C3 methylenedioxy group probably due to 
its less steric hindrance; however, the coexistence of C2 methoxy and C3 methoxy groups with 
larger steric hindrance seems to prevent the compound from approaching and forming H-bonds 
with RXRα Arg371, thereby failing to activate RXRα and suppress colon cancer. Second, the 
presence of single C9 or C10 methoxy group, C10-C11 methylenedioxy group or C9/C10 
bismethoxy groups on the tail region of berberine may be necessary to make maximal interaction 
with the hydrophobic groups in the Site X of RXRα/LBD through Van Der Waals contacts; while 
the presence of 10,11-dimethoxy groups or single C12 methoxy group led to poor RXRα binding 
potential and biological activity, which may be attributed to the unfavorable steric effect. These 
features may help guide the further improvement of current compounds. 
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As we mentioned above, berberine binds RXRα in a unique mode. Unlike other RXRα ligands 
such as 9-cis-RA, berberine lacks a classic carboxyl group which is crucial for 9-cis-RA to interact 
with RXRα through forming a salt bridge with Arg316 in the classical ligand-binding mode of 
RXRα49. These distinct structures and binding modes of berberine and 9-cis-RA lead to different 
conformational changes of RXRα and consequently some diverse biological functions. 
Furthermore, the concomitant binding of berberine and 9-cis-RA to RXRα/LBD is possibly the 
main reason for their synergistic effect on RXRα-dependent transcriptional activity and colon 
cancer cell growth, suggesting a great potential for the combination of berberine and 9-cis-RA to 
treat colon cancer26. Indeed, combination therapy with different drugs for cancer has long been a 
successful way to increase drug efficacy, reduce toxicity and reverse drug resistance. For instance, 
clinical trials have proven that the combination of all-trans retinoic acid and arsenic trioxide is a 
feasible treatment in acute promyelocytic leukemia with a higher cure rate and less relapse50. In 
the present study, B-12 combined with 9-cis-RA had a more significant synergistic effect than 
berberine with 9-cis-RA (Figure S7), suggesting that B-12 might be a better drug than berberine 
for combined drug therapy. Besides, in mouse model we also found that, unlike other RXRα 
ligands, B-12 did not show side effects such as hypertriglyceridemia, hypercalcemia, and 
hypercholesterolemia (Table 3), which are the main reasons for the limited use of the existing 
RXRα agonists in clinical practice; moreover, B-12 did not induce obvious hepatorenal toxicity or 
hepatomegaly as most anti-tumor drugs did (Table 3, Figure 6 and Figure S6). Further studies, 
including in vitro and in vivo experiments, are still required to elucidate its potential.
 In conclusion, this study describes a novel SAR design of berberine analogues based on the 
structural features of berberine analogues as RXRα activators, which might serve as a theoretical 
basis for designing and evaluating the next generation of berberine-based drugs against colon 
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cancer. Especially, we developed B-12 as a better RXRα activator than berberine, with stronger 
anticancer activity, higher bioavailability, and comparative tumor selectivity. 
■ EXPERIMENTAL SECTION
Chemistry
All reactions were carried out under an argon atmosphere with dry solvents under anhydrous 
conditions unless otherwise stated. All the chemicals were purchased commercially and used 
without further purification unless otherwise stated. The boiling point of petroleum ether (PE) is 
between 60-90 ºC. Tetrahydrofuran (THF) was distilled from sodium-benzophenone; 
Dichloromethane (CH2Cl2) was distilled from calcium hydride. Toluene was distilled from sodium 
under argon atmosphere. Reactions were monitored by thin-layer chromatography (TLC) carried 
out on 0.25 mm Qingdao silica gel plates (F254) using UV lights as the visualizing agent and 
KMnO4. Flash column chromatography was performed over Qingdao silica gel (200-300 mesh). 
Infrared spectra were recorded on a Nicolet AVATER FTIR330 spectrometer as thin film and are 
reported in reciprocal centimeter (cm-1). High-resolution mass spectra (HRMS) were recorded on 
a Micromass QTOF2 Quadrupole/Time-of-Flight Tandem mass spectrometer using electron spray 
ionization. NMR spectra were recorded on Bruker AV-400 and Bruker AV-500 instruments and 
were calibrated using residual undeuterated solvents (CHCl3, δH = 7.26; DMSO-d6, δH = 2.50; 
CD3OD, δH = 3.31) and deuterated solvents (CDCl3, δC = 77.0; CD3OD, δC = 49.0; DMSO-d6, δC 
= 39.5) as internal references. The data for 1H NMR are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet or unresolved, brs = broad singlet), 
coupling constants (Hz) and integration. The structure and purity of B1-B15 was determined by 
qNMR with triphenylmethane as an internal standard. The purity of key compounds (B-2, B-8, B-
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9, B-10, B-12) were also analyzed by HPLC. The purity of all the compounds were determined to 
be > 95%. 
 
General Synthetic Procedures for the Berberine Analogues B1-B15 (B-12 as an Example)
2-(2-Bromo-6-methoxyphenyl)-1,3-dioxolane (5a). With a modified Donohoe’s procedure: To a 
stirred mixture of 2-bromo-6-methoxybenzaldehyde (2.15 g, 10.0 mmol) and ethylene glycol (2.78 
mL, 50 mmol) in toluene (200 mL) was added HC(OEt)3 (5.0 mL, 30.0 mmol) and p-TSA (190 
mg, 1.0 mmol) in sequence. The resultant mixture was heated at 90 C for 18 h and then cooled to 
room temperature and extracted with Et2O. The combined layers were washed with saturated brine, 
dried over MgSO4 and concentrated in vacuo. Purification of the residue by flash chromatography 
(PE/EtOAc = 10:1) afforded 5a as a colorless oil (2.56 g, 99%). 1H NMR (500 MHz, CDCl3) δ 
7.17 – 7.14 (m, 1H), 7.10 (dd, J = 10.6, 5.6 Hz, 1H), 6.83 (dd, J = 8.2, 1.0 Hz, 1H), 6.44 (s, 1H), 
4.27 – 4.19 (m, 2H), 4.01 – 3.96 (m, 2H), 3.78 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 159.7, 
130.8, 126.1, 123.7, 123.5, 110.7, 101.1, 65.7, 55.9. HRMS (ESI, m/z) calcd for C10H11BrO3, [M]+: 
257.9892, found: 257.9898.
3-Methoxyphenethyl pivalate (2a). To a solution of 3-methyoxyphenylacetic acid (1.66 g, 10.0 
mmol) in THF at 0 C was added borane-THF complex solution (20.0 mL, 20.0 mmol). The 
mixture was allowed to warm to room temperature and stirred for 2 h before being quenched with 
1 M aqueous solution of NaOH. The resulting mixture was extracted with Et2O. The combined 
organic layers were washed with saturated brine, dried over MgSO4 and concentrated in vacuo. 
The residue was redissolved in CH2Cl2 (50 mL) and cooled to 0 C. To the mixture was added 
pyridine (0.8 mL, 20.0 mmol) and pivaloyl chloride (2.78 mL, 20.0 mmol) sequentially. The 
resulting mixture was allowed to warm to room temperature and stirred for 18 h. The reaction was 
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quenched with H2O (5 mL) and extracted with CH2Cl2. The combined organic layers were washed 
with saturated brine, dried over MgSO4 and concentrated in vacuo. Purification of the residue by 
flash chromatography (PE/EtOAc = 20:1) afforded 2a as a colorless oil (2.12 g, 90%). 1H NMR 
(500 MHz, CDCl3) δ 7.17 (t, J = 7.75 Hz, 1H), 6.78 (d, J = 7.6 Hz, 1H), 6.77 – 6.72 (m, 2H), 4.25 
(t, J = 6.8 Hz, 2H), 3.75 (s, 3H), 2.88 (t, J = 6.8 Hz, 2H), 1.15 (s, 9H). 13C NMR (125 MHz, CDCl3) 
δ 178.1, 159.5, 139.3, 129.2, 121.1, 114.4, 111.7, 64.6, 54.8, 38.6, 35.0, 26.9. HRMS (ESI, m/z) 
calcd for C14H20O3, [M+H]+: 237.1491, found: 237.1487.
2-Acetyl-5-methoxyphenethyl pivalate (3a). To a solution of 2a (1.89 g, 8.0 mmol) in acetic 
anhydride (20 mL) at 0 C was added ZnCl2 (5.45 g, 40.0 mmol). The mixture was allowed to 
room temperature and stirred for 18 h. The solution was concentrated in vacuo and then the residue 
was redissolved in EtOAc. The mixture was washed with saturated aqueous solution of NaHCO3, 
water and brine. The organic phase was dried over MgSO4 and concentrated in vacuo. Purification 
of the residue by flash chromatography (PE/EtOAc = 10:1) afforded 3a as a colorless oil (1.66g, 
75%). 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.5 Hz, 1H), 6.82 – 6.76 (m, 2H), 4.30 (t, J = 6.6 
Hz, 2H), 3.84 (s, 3H), 3.26 (t, J = 6.6 Hz, 2H), 2.56 (s, 3H), 1.14 (s, 9H). 13C NMR (125 MHz, 
CDCl3) δ 199.1, 178.3, 151.4, 146.8, 133.4, 129.3, 114.9, 113.5, 64.8, 55.8, 38.6, 33.6, 29.1, 27.1. 
HRMS (ESI, m/z) calcd for C16H22O4, [M+Na]+: 301.1416, found: 301.1410.
2-(2-(2-(1,3-Dioxolan-2-yl)-3-methoxyphenyl)acetyl)-5-methoxyphenethyl pivalate (6a). To a 
stirred solution of 5a (596 mg, 2.3 mmol) and 3a (1.28 g, 4.6 mmol) in THF (10 mL) in a 30 mL 
vial was added Cs2CO3 (1.87 g, 5.75 mmol) and (Amphos)2PdCl2 (81 mg, 0.115 mmol). The 
resulting solution was bubbled with argon for a minimum of 10 min and then quickly equipped 
with a Teflon septum. The mixture was heated at 90 °C for 18 h. The mixture was then cooled to 
room temperature and quenched with water and extracted with Et2O. The combined organic layers 
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were washed with saturated brine, dried over MgSO4 and concentrated in vacuo. Purification of 
the residue by flash chromatography (PE/EtOAc = 4:1) afforded 6a as a colorless oil (756 mg, 
72%). 1H NMR (500 MHz, CDCl3) δ 7.90 – 7.85 (m, 1H), 7.34 – 7.28 (m, 1H), 6.87 – 6.77 (m, 
4H), 6.24 (s, 1H), 4.40 (s, 2H), 4.33 (t, J = 6.6 Hz, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 3.80 – 3.75 (m, 
2H), 3.74 – 3.67 (m, 2H), 3.24 (t, J = 6.6 Hz, 2H), 1.15 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 
198.7, 178.5, 161.5, 159.0, 142.2, 137.1, 131.7, 130.3, 129.9, 125.4, 121.2, 117.9, 111.5, 109.9, 
98.7, 64.9, 64.5, 55.8, 55.3, 44.9, 38.7, 34.1, 27.3. HRMS (ESI, m/z) calcd for C26H32O7, [M+H]+: 
457.2226, found: 457.2221.
3,9-Dimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-12). To 6a (723 
mg, 1.58 mmol) in a 15 mL vial was added 1 M solution of NH4Cl in 3:1 of EtOH/H2O (4 mL). 
The solution was bubbled with argon for a minimum of 10 min and quickly equipped with a Teflon 
septum. The stirred mixture was heated at 90 °C for 18 h. Then the solution was heated at 110 C 
for another 48 h. The mixture was cooled to room temperature, and concentrated with silica gel in 
vacuo. Purification of the residue by flash chromatography (CH2Cl2/MeOH = 10:1) afforded a 
crude product. The crude product was recrystallized in methanol/Et2O to give B-12 as a pale yellow 
solid (368 mg, 71%). The purity of the title compound was determined to be > 95% by qNMR. 1H 
NMR (500 MHz, DMSO-d6) δ 9.92 (s, 1H), 8.96 (s, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.11 (t, J = 8.1 
Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.12 (dd, J = 8.7, 2.6 Hz, 1H), 7.08 (d, 
J = 2.5 Hz, 1H), 4.94 (t, J = 6.3 Hz, 2H), 4.13 (s, 3H), 3.88 (s, 3H), 3.31 – 3.26 (m, 2H). 13C NMR 
(125 MHz, DMSO-d6) δ 171.5, 166.7, 155.0, 149.8, 148.8, 147.9, 147.1, 137.7, 128.9, 128.8, 
128.2, 127.2, 123.9, 122.7, 118.2, 66.2, 65.2, 64.3, 36.1. HRMS (ESI, m/z) calcd for C19H18NO2, 
[M]+: 292.1332, found: 292.1329.
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5,6-Dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride (B-1). This 
compound was prepared from 2-bromobenzaldehyde and 2-(benzo[d][1,3]dioxol-5-yl)acetic acid 
using the above method. The purity of the title compound was determined to be > 95% by qNMR. 
1H NMR (500 MHz, CDCl3) δ 8.44 – 8.39 (m, 1H), 7.62 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 7.55 – 
7.51 (m, 1H), 7.43 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.26 (d, J = 1.6 Hz, 2H), 6.84 (s, 1H), 6.72 (s, 
1H), 6.01 (s, 2H), 4.36 – 4.32 (m, 2H), 2.93 – 2.89 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 162.1, 
148.7, 147.4, 137.4, 136.7, 132.2, 130.3, 127.9, 126.2, 126.0, 124.6, 123.7, 107.9, 105.0, 101.8, 
101.5, 39.7, 28.5. 1H NMR (500 MHz, DMSO-d6) δ 10.09 (d, J = 14.6 Hz, 1H), 9.04 (s, 1H), 8.43 
(d, J = 8.3 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.19 (t, J = 7.6 Hz, 1H), 7.97 (t, J = 7.5 Hz, 1H), 7.87 
(s, 1H), 7.11 (s, 1H), 6.18 (s, 2H), 4.88 (t, J = 6.0 Hz, 2H), 3.24 (t, J = 6.3 Hz, 2H). 13C NMR (125 
MHz, DMSO-d6) δ 150.4, 148.3, 147.8, 141.7, 138.4, 137.5, 136.7, 134.4, 131.1, 130.5, 129.9, 
129.2, 127.2, 125.5, 120.5, 120.4, 114.3, 108.5, 106.4, 105.8, 105.1, 102.2, 55.2, 26.3. HRMS 
(ESI, m/z) calcd for C18H14NO2, [M]+: 276.1019, found: 276.1016. Spectroscopic date were 
consistent with those previously reported.42
5,6-Dihydro-[1,3]dioxolo[4',5':6,7]isoquinolino[3,2-a][1,3]dioxolo[4,5-g]iso quinolin-7-ium 
chloride (B-2, pseudocoptisine). This compound was prepared from 6-
bromobenzo[d][1,3]dioxole-5-carbaldehyde and 2-(benzo[d][1,3]dioxol-5-yl)acetic acid using the 
above method. The purity of the title compound was determined to be > 95% by qNMR. 1H NMR 
(400 MHz, DMSO-d6) δ 9.57 (s, 1H), 8.77 (s, 1H), 7.74 (s, 1H), 7.71 (s, 1H), 7.54 (s, 1H), 7.09 (s, 
1H), 6.42 (s, 2H), 6.17 (s, 2H), 4.76 (t, J = 6.4 Hz, 2H), 3.18 (t, J = 6.4 Hz, 2H). 13C NMR (100 
MHz, DMSO-d6) δ 156.4, 151.3, 150.4, 148.1, 146.3, 139.2, 139.1, 131.3, 124.0, 120.7, 119.4, 
108.9, 105.9, 104.3, 104.2, 103.1, 102.5, 54.9, 26.8. HRMS (ESI, m/z) calcd for C19H14NO4, [M]+: 
320.0917, found: 320.0915. Spectroscopic date were consistent with those previously reported.37
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3,10,11-Trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-3). This 
compound was prepared from 2-bromo-4,5-dimethoxybenzaldehyde and 2-(3-
methoxyphenyl)acetic acid using the above method. The purity of the title compound was 
determined to be > 95% by qNMR.1H NMR (500 MHz, CD3OD) δ 9.35 (s, 1H), 8.59 (s, 1H), 8.09 
(d, J = 8.8 Hz, 1H), 7.62 (s, 1H), 7.60 (s, 1H), 7.09 (dd, J = 8.8, 2.5 Hz, 1H), 7.03 (d, J = 2.5 Hz, 
1H), 4.82 (t, J = 6.6 Hz, 2H), 4.12 (s, 3H), 4.06 (s, 3H), 3.91 (s, 3H), 3.32 (t, J = 6.6 Hz, 2H). 13C 
NMR (125 MHz, CD3OD) δ 162.6, 158.5, 153.1, 144.6, 139.2, 137.6, 136.9, 127.4, 122.8, 119.4, 
117.7, 114.4, 113.0, 105.9, 104.9, 56.1, 55.7, 54.8, 54.7, 27.2. HRMS (ESI, m/z) calcd for 
C20H20NO3, [M]+: 322.1438, found: 322.1435.
10,11-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquin olin-7-ium 
chloride (B-4, pseudoberberine). This compound was prepared from 2-bromo-4,5-
dimethoxybenzaldehyde and 2-(benzo[d][1,3]dioxol-5-yl)acetic acid using the above method. The 
purity of the title compound was determined to be > 95% by qNMR.1H NMR (500 MHz, DMSO-
d6) δ 9.57 (s, 1H), 8.77 (s, 1H), 7.73 (s, 1H), 7.72 (s, 1H), 7.59 (s, 1H), 7.10 (s, 1H), 6.17 (s, 2H), 
4.78 (t, J = 6.3 Hz, 2H), 4.07 (s, 3H), 4.00 (s, 3H), 3.20 (t, J = 6.3 Hz, 2H). 13C NMR (125 MHz, 
DMSO-d6) δ 157.5, 152.3, 149.8, 147.7, 145.5, 138.2, 136.6, 130.7, 122.1, 118.2, 108.5, 106.6, 
105.3, 102.1, 56.7, 56.4, 54.5, 26.4. HRMS (ESI, m/z) calcd for C20H18NO4+, [M]+: 336.1236, 
found: 336.1234. Spectroscopic date were consistent with those previously reported.51
2,3,10,11-Tetramethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-5, 
pseudopalmatine). This compound was prepared from 2-bromo-4,5-dimethoxybenzaldehyde and 
2-(3,4-dimethoxyphenyl)acetic acid using the above method. The purity of the title compound was 
determined to be > 95% by qNMR.1H NMR (500 MHz, DMSO-d6) δ 9.58 (s, 1H), 8.88 (s, 1H), 
7.72 (s, 1H), 7.67 (s, 1H), 7.62 (s, 1H), 7.10 (s, 1H), 4.80 (t, J = 6.3 Hz, 2H), 4.08 (s, 3H), 4.00 (s, 
Page 31 of 54
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
32
3H), 3.94 (s, 3H), 3.87 (s, 3H), 3.22 (t, J = 6.3 Hz, 2H). 13C NMR (125 MHz, DMSO-d6) δ 157.4, 
152.2, 151.5, 148.7, 145.6, 138.4, 136.6, 128.6, 122.0, 118.9, 118.0, 111.3, 108.5, 106.5, 105.3, 
56.6, 56.3, 56.0, 55.9, 54.6, 26.1. HRMS (ESI, m/z) calcd for C21H22NO4, [M]+: 352.1543, found: 
352.1540. Spectroscopic date were consistent with those previously reported.51
2,3-Dimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-6). This 
compound was prepared from 2-bromobenzaldehyde and 2-(3,4-dimethoxyphenyl)acetic acid 
using the above method. The purity of the title compound was determined to be > 95% by qNMR. 
1H NMR (500 MHz, CD3OD) δ 9.81 (s, 1H), 8.93 (s, 1H), 8.38 (d, J = 8.3 Hz, 1H), 8.30 (d, J = 
8.4 Hz, 1H), 8.17 – 8.13 (m, 1H), 7.96 – 7.92 (m, 1H), 7.72 (s, 1H), 7.07 (s, 1H), 4.95 (t, J = 6.4 
Hz, 2H), 4.01 (s, 3H), 3.95 (s, 3H), 3.34 (t, J = 6.4 Hz, 2H). 13C NMR (125 MHz, CD3OD) δ 154.2, 
151.1, 151.0, 142.0, 140.7, 138.0, 131.7, 131.0, 130.5, 128.6, 127.4, 121.7, 120.3, 112.3, 110.3, 
57.3, 57.1, 56.7, 27.7. HRMS (ESI, m/z) calcd for C19H18NO2, [M]+: 292.1332, found: 292.1330.
3-Methoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-7). This compound 
was prepared from 2-bromobenzaldehyde and 2-(3-methoxyphenyl)acetic acid using the above 
method. The purity of the title compound was determined to be > 95% by qNMR. 1H NMR (500 
MHz, CD3OD) δ 9.83 (s, 1H), 8.81 (s, 1H), 8.38 (d, J = 8.3 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.16 
– 8.09 (m, 2H), 7.94 – 7.87 (m, 1H), 7.07 (dd, J = 8.8, 2.6 Hz, 1H), 7.02 (d, J = 2.5 Hz, 1H), 4.95 
(t, J = 6.3 Hz, 2H), 3.89 (s, 3H), 3.36 (t, J = 6.3 Hz, 2H). 13C NMR (125 MHz, CD3OD) δ 164.2, 
151.0, 142.0, 140.6, 138.5, 138.0, 131.6, 131.0, 129.4, 128.5, 127.3, 121.4, 120.6, 116.0, 114.3, 
57.0, 56.3, 28.4. HRMS (ESI, m/z) calcd for C18H16NO, [M]+: 262.1226, found: 262.1224.
3-Methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[2,1-b]isoquinolin-7-ium chloride (B-
8). This compound was prepared from 6-bromobenzo[d][1,3]dioxole-5-carbaldehyde and 2-(3-
methoxyphenyl)acetic acid using the above method. The purity of the title compound was 
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determined to be > 95% by qNMR.1H NMR (500 MHz, DMSO-d6) δ 9.57 (s, 1H), 8.79 (s, 1H), 
8.11 (d, J = 8.7 Hz, 1H), 7.71 (s, 1H), 7.60 (s, 1H), 7.12 (dd, J = 8.7, 2.3 Hz, 1H), 7.08 (d, J = 2.2 
Hz, 1H), 6.41 (s, 1H), 4.79 (t, J = 6.0 Hz, 2H), 3.88 (s, 3H), 3.27 (t, J = 6.0 Hz, 2H). 13C NMR 
(125 MHz, DMSO-d6) δ 164.1, 158.3, 153.0, 146.5, 141.2, 138.4, 129.0, 125.6, 120.6, 119.9, 
119.8, 115.8, 114.4, 105.4, 104.7, 103.9, 64.3, 56.2, 28.4. HRMS (ESI, m/z) calcd for C19H16NO3, 
[M]+: 306.1125, found: 306.1121.
10-Methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride (B-
9). This compound was prepared from 2-bromo-5-methoxybenzaldehyde and 2-
(benzo[d][1,3]dioxol-5-yl)acetic acid using the above method. The purity of the title compound 
was determined to be > 95% by qNMR. 1H NMR (500 MHz, DMSO-d6) δ 9.84 (s, 1H), 8.99 (s, 
1H), 8.17 (d, J = 9.1 Hz, 1H), 7.85 (dd, J = 9.1, 2.4 Hz, 1H), 7.81 (s, 1H), 7.77 (d, J = 2.4 Hz, 1H), 
7.10 (s, 1H), 6.18 (s, 2H), 4.87 (t, J = 6.3 Hz, 2H), 4.00 (s, 3H), 3.22 (t, J = 6.3 Hz, 2H). 13C NMR 
(125 MHz, DMSO-d6) δ 160.0, 149.9, 147.8, 147.7, 138.0, 134.4, 130.6, 129.8, 129.1, 127.3, 
120.4, 108.4, 106.5, 105.5, 102.1, 56.2, 55.6, 55.2, 26.3. HRMS (ESI, m/z) C19H16NO3, [M]+: 
306.1125, found: 306.1122. Spectroscopic date were consistent with those previously reported.42
3,9,10-Trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-10). This 
compound was prepared from 6-bromo-2,3-dimethoxybenzaldehyde and 2-(3-
methoxyphenyl)acetic acid using the above method. The purity of the title compound was 
determined to be > 95% by qNMR.1H NMR (500 MHz, DMSO-d6) δ 8.96 (s, 1H), 8.32 (s, 1H), 
8.18 (d, J = 9.2 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.04 (d, J = 9.1 Hz, 1H), 7.10 (dd, J = 8.7, 2.6 
Hz, 1H), 7.07 (d, J = 2.3 Hz, 1H), 4.96 (t, J = 6.2 Hz, 2H), 4.09 (s, 3H), 4.06 (s, 3H), 3.87 (s, 3H), 
3.28 (t, J = 6.2 Hz, 2H). 13C NMR (125 MHz, DMSO-d6) δ 162.0, 150.7, 145.8, 138.3, 137.6, 
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133.6, 128.2, 127.2, 124.0, 121.9, 120.2, 120.0, 114.9, 113.7, 79.7, 62.4, 60.2, 57.5, 56.1, 27.2. 
HRMS (ESI, m/z) calcd for C20H20NO3, [M]+: 322.1438, found: 322.1439.
2,3,9,10-Tetramethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-11, 
palmatine). This compound was prepared from 6-bromo-2,3-dimethoxybenzaldehyde and 2-(3,4-
dimethoxyphenyl)acetic acid using the above method. The purity of the title compound was 
determined to be > 95% by qNMR.1H NMR (500 MHz, CD3OD) δ 9.73 (s, 1H), 8.76 (s, 1H), 8.06 
(d, J = 8.8 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.59 (s, 1H), 7.01 (s, 1H), 4.93 (s, 2H), 4.19 (s, 3H), 
4.07 (s, 3H), 3.97 (s, 3H), 3.92 (s, 3H), 3.27 (s, 2H). 13C NMR (125 MHz, CD3OD) δ 153.7, 151.8, 
150.8, 146.3, 145.6, 139.7, 135.2, 130.0, 127.9, 124.5, 123.2, 121.2, 120.4, 112.2, 109.9, 62.6, 
57.6, 57.3, 57.1, 56.7, 27.8. 1H NMR (500 MHz, DMSO-d6) δ 9.90 (s, 1H), 9.08 (s, 1H), 8.21 (d, 
J = 9.1 Hz, 1H), 8.04 (d, J = 9.1 Hz, 1H), 7.73 (s, 1H), 7.09 (s, 1H), 4.96 (t, J = 6.3 Hz, 2H), 4.10 
(s, 3H), 4.07 (s, 3H), 3.94 (s, 3H), 3.87 (s, 3H), 3.23 (t, J = 6.3 Hz, 2H). 13C NMR (125 MHz, 
DMSO-d6) δ 151.5, 150.2, 148.7, 145.4, 143.6, 137.7, 133.1, 128.6, 126.8, 123.4, 121.3, 119.9, 
118.9, 111.3, 108.8, 61.9, 57.0, 56.2, 55.9, 55.3, 26.0. HRMS (ESI, m/z) calcd for C21H22NO4, 
[M]+: 352.1543, found: 352.1539. Spectroscopic date were consistent with those previously 
reported.37
2,3,9-Trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-13). This 
compound was prepared from 2-bromo-6-methoxybenzaldehyde and 2-(3,4-
dimethoxyphenyl)acetic acid using the above method. The purity of the title compound was 
determined to be > 95% by qNMR. 1H NMR (500 MHz, CD3OD) δ 9.80 (s, 1H), 8.83 (s, 1H), 
7.92 (d, J = 8.3 Hz, 1H), 7.86 (t, J = 8.0 Hz, 1H), 7.63 (s, 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.07 (s, 
1H), 4.94 (t, J = 6.3 Hz, 2H), 4.17 (s, 3H), 4.00 (s, 3H), 3.94 (s, 3H), 3.35 (t, J = 6.3 Hz, 2H). 13C 
NMR (125 MHz, CD3OD) δ 154.5, 152.8, 149.5, 149.2, 140.1, 131.2, 129.2, 126.7, 120.7, 119.0, 
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114.8, 113.7, 111.0, 108.9, 55.9, 55.80, 55.4, 29.3, 26.3. HRMS (ESI, m/z) calcd for C20H20NO3, 
[M]+: 322.1438, found: 322.1440.
2,3,12-Trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium chloride (B-14). This 
compound was prepared from 2-bromo-3-methoxybenzaldehyde and 2-(3,4-
dimethoxyphenyl)acetic acid using the above method. The purity of the title compound was 
determined to be > 95% by qNMR.1H NMR (500 MHz, CD3OD) δ 9.82 (s, 1H), 8.81 (s, 1H), 8.07 
(t, J = 8.1 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.67 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.05 (s, 1H), 
4.96 – 4.91 (m, 2H), 4.18 (s, 3H), 4.00 (s, 3H), 3.94 (s, 3H), 3.32 – 3.28 (m, 2H). 13C NMR (125 
MHz, CD3OD) δ 157.8, 152.7, 149.4, 145.2, 140.7, 140.0, 138.5, 129.2, 119.5, 118.8, 118.6, 118.4, 
110.9, 108.9, 108.1, 62.8, 55.9, 55.7, 55.3. HRMS (ESI, m/z) calcd for C20H20NO3, [M]+: 
322.1438, found: 322.1439.
12-Methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride (B-
15). This compound was prepared from 2-bromo-3-methoxybenzaldehyde and 2-
(benzo[d][1,3]dioxol-5-yl)acetic acid using the above method. The purity of the title compound 
was determined to be > 95% by qNMR. 1H NMR (500 MHz, CD3OD) δ 9.80 (s, 1H), 8.71 (s, 1H), 
7.90 (d, J = 8.2 Hz, 1H), 7.84 (t, J = 8.0 Hz, 1H), 7.58 (s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 6.93 (s, 
1H), 6.08 (s, 2H), 4.97 – 4.90 (m, 3H), 4.15 (s, 3H), 3.29 – 3.24 (m, 2H). 13C NMR (125 MHz, 
CD3OD) δ 154.5, 151.0, 149.2, 148.5, 139.9, 131.4, 131.2, 130.9, 126.8, 120.7, 120.3, 114.9, 
113.7, 108.1, 105.3, 102.4, 55.8, 55.7, 26.7. HRMS (ESI, m/z) calcd for C19H16NO3, [M]+: 
306.1125, found: 306.1121.
■ BIOLOGICAL ASSAY PROTOCOLS
Chemicals and reagents
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Berberine (cat. #141433-60-5) and 9-cis-RA (cat. #5300-03-8) were purchased from Sigma-
Aldrich, St. Louis, MO, USA. Rabbit anti-p21WAF1/CIP1 (cat. #2947), anti-Ki67 (cat. #9449) and 
mouse anti-β-catenin (cat. #6582), anti-Cdc2 (cat. #9116) antibodies were purchased from Cell 
Signaling Technology, Boston, MA, USA. Rabbit anti-c-Myc (cat. #40764) antibodies were 
purchased from Signalway Antibody, Baltimore, USA. Rabbit anti-PCNA (cat. #ab2426) antibody 
was purchased from Abcam, Boston, MA, USA. Rabbit anti-RXRα was purchased from Santa 
Cruz Biotechnology, Santa Cruz, CA, USA. 
Molecular docking study
To further understand the relationship between berberine (and its analogues) and protein 
RXRα/LBD, molecular docking simulations were performed. The 3D structure of RXRα/LBD 
protein was obtained from the Protein Data Bank using PDB ID: 3FUG. Then the 3D structure 
was prepared by removing the water molecules from the structure and defining binding sites using 
APOPDB2RECEPTOR utility implemented in Openeye software suits. Small molecule structures 
were prepared by SYBYL2.0 and conformational enumeration was done by OMEGA utility 
implemented in Openeye software suits, with all parameters set default. After that FRED docking 
tool was used for molecular docking simulations and its Chemgauss4 score was used for ranking 
the pose of each docked compound. Conformation with the highest score was used for further 
evaluation. Interaction between small molecule and protein was shown by VIDA.
Cell culture
Human colon cell lines HIEC-6 were obtained from ATCC (Virginia, USA). The colon cancer 
cell lines HCT116 and SW620 were obtained from Cell Bank of Type Culture Collection of 
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Chinese Academy of Sciences (Shanghai, China). Human KM12C colon cancer cell line, 
established from a Duke’s B2 primary colon cancer, was kindly provided by Professor I. J. Fidler 
(M.D. Anderson Cancer Center, Houston, TX, USA). Mouse embryonic fibroblast MEF cell lines 
were kindly provided by Professor Bo-an Li (Xiamen University, China). Mycoplasma testing was 
regularly conducted to assure that all these cell lines were mycoplasma-free at all times. KM12C 
were maintained in MEM culture medium (Gibco, Grand Island, NY, USA) supplemented with 10 
% fetal bovine serum (FBS, Invitrogen; Thermo Fisher Scientific), 100 IU/mL penicillin (Life 
Technologies, Carlsbad, CA, USA), 100 µg/mL streptomycin (Life Technologies), 1% non-
essential amino acids (Gibco) and 1% vitamin solution (Gibco). HIEC-6 were maintained in MEM 
culture medium (Gibco, Grand Island, NY, USA) supplemented with 4 % fetal bovine serum (FBS, 
Invitrogen; Thermo Fisher Scientific), 100 IU/mL penicillin (Life Technologies, Carlsbad, CA, 
USA), 100 µg/mL streptomycin (Life Technologies), 20 mM HEPES (Gibco),10 mM GlutaMAX 
(Gibco Catalog No. 35050) and 10 ng/mL Epidermal Growth Factor (EGF) (Gibco). MEF cells 
were cultured in DMEM high-glucose medium (Gibco) prepared with 10% of fetal bovine serum, 
100 IU/mL penicillin and 100 µg/mL streptomycin. All cell lines were maintained at 37 °C in an 
atmosphere of 95% air and 5% CO2.
Transfection and dual-luciferase reporter assays
The cells were inoculated into 24 well culture plates. After 24 h, different luciferase reporter 
genes and other different expression vectors as required were transfected with liposome 
transfection reagent Lipfectamine 2000 (Invitrogen, Gaithersburg, MD, USA) according to the 
manufacturer’s recommendations. Luciferase assays were carried out according to the instructions 
of the Dual-Luciferase Reporter Assay Kit (Promega, Madison, WI, USA). Briefly, after 20 h of 
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transfection, berberine or berberine analogues were added for 15 h and then the medium was 
carefully removed. 100 µL 1× Passive Lysis Buffer was added into each hole at 4 °C for 1 h, the 
Firefly and renilla luciferase activity was detected by GloMax 20/20 Luminometer (Promega).
Cell proliferation assay 
Cell proliferation rates were determined by MTT assay or EdU assay. In MTT assay, briefly, the 
cells were seeded in 96-well plates at a density of 1×104 cells/well. After incubated at 37 °C 
overnight, the cells were treated with berberine or B-12 at different concentrations for 15 h, then 
20 µL MTT (5 mg/mL) solution was added to each well and incubated for 4 h at 37 °C. Four hours 
later, the medium was removed carefully. 150 µL DMSO was added to each well to dissolve 
formazan crystals. The absorbance at 570 nm was measured using a Model 680 microplate reader 
(Bio-Rad, Hercules, CA, USA). The EdU assay was performed in a 96-well plate by EdU assay 
kit (Ribobio, China) according to the instruction, and the cells were examined under a fluorescence 
microscope.
Purification of His-RXRα-LBD fusion proteins
The constructed pET15b-RXR-LBD expression plasmid was transformed into Ecoli strain BL21 
(DE3) to express the target protein. The strain was cultured in fresh LB medium containing 
ampicillin at 37 °C and 250 rpm until OD600 reached 0.6. Isopropyl-1-thio-b-D-galactopyranoside 
(IPTG) with final concentration of 0.1 mM was added. After 16 h of induction at 16 °C, the strain 
was centrifuged at 5000 rpm for 20 min to collect. The protein was purified according to the 
standard His-tag fusion protein method. Briefly, the bacteria were resuspended with lysis buffer 
(50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole, 0.5% (v/v) Triton X-100) 
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supplemented with PMSF (1 mM), sonicated, and centrifuged at 10000 rpm, at 4 °C for 30 min. 
The supernatant was added to NiNTA resin chromatography affinity column, then incubated at 4 
°C for 1 h, and washed twice with 800 μL wash buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 
50 mM imidazole). Finally, the target protein was eluted with 100 μL elution buffer (50 mM 
NaH2PO4 pH 8.0, 300 mM NaCl, 250 mM imidazole). After the purity of the collected samples 
was detected by discontinuous SDS-PAGE, the components with a purity of more than 90% were 
dialyzed into the required buffer for the following experiments.
Saturation Transfer Difference (STD) NMR experiment 
The NMR samples used for STD experiment contain 600 μL 0.01 mM PBS buffer solution (pH 
7.4) consisting of 10 μM RXRα/LBD, 200 µM berberine or B-12, 5% DMSO and 5% D2O. All 
NMR experiments were performed on Bruker 800 MHz AVANCE III HD equipped with a 
cryoprobe at 25 °C. The Bruker pulse program stddiffgp19.3 was used to collect STD NMR data 
and the saturation time was set to 2 sec. The STD spectra were processed and analyzed by Topspin 
3.5.
Fluorescence titration measurements  
The fluorescence titration measurements were carried out on a VARIAN spectrofluorometer 
model Varian Eclipse. The sample quartz cuvette path length was 1 cm, and the excitation and 
emission slit widths were set as 5 nm. Then the fluorescence spectra of RXRα and the RXRα–
berberine complex were recorded in the wavelength range 290–600 nm after excitation at 280 nm. 
The change in fluorescence intensity was observed by continuous stirring varying concentrations 
of berberine (2-30 μM) to the fixed concentration of RXRα (1 μM) in PBS buffer solution (pH 
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7.4). The DMSO titrated with an equal amount of berberine was also measured and subtracted 
from their respective samples to correct its effect. Each spectrum was measured three times.
Circular dichroism (CD) spectroscopy
CD spectra were measured with a Jasco J-810 spectropolarimeter (Jasco Corporation, Tokyo, 
Japan) at 25 °C. Instrument path length was set to 0.1 cm, and wavelength range at 180-260 nm 
(protein secondary structure). The band width was set to 1 nm with the response time of 1 s and a 
scanning speed of 20 nm/min. All measurements were detected in the 0.01 M phosphate buffer. 
Purification of His-RXRα-LBD was dilute to 1 μM in phosphate buffer, and the concentration of 
berberine or B-12 was 5 μM (DMSO concentration was 0.01%). For the displacement studies, the 
spectra were recorded 5 min after addition of the berberine to the His-RXRα/LBD solution. 
Average of 3 scans were collected for each spectrum.
Real-time PCR
Total RNA was extracted with Trizol (Invitrogen) reagent according to the manufacturer’s 
instructions. Then 1 μg mRNA was reversely transcribed to cDNA by Reverse Transcription 
System (Promega). The mRNA expression levels of target genes were detected by LightCycler 96 
Real-Time PCR System (Roche Diagnostics GmbH, Mannheim, Germany) with SYBR Premix 
EX Taq (TaKaRa, Japan). GAPDH gene level was set as an internal control.
The primers were listed below:
GAPDH:
Forward: 5′- TGCACCACCAACTGCTTAGC-3′
Reverse: 5′ GGCATGGACTGTGGTCATGAG-3′;
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c-Myc:
Forward: 5' GGGGCTTTATCTAACTCGC 3'
Reverse: 5' CTATGGGCAAAGTTTCGTG 3'
Cdc2: 
Forward: 5' AAACTACAGGTCAAGTGGTAGCC3'
Reverse: 5' TCCTGCATAAGCACATCCTGA3'
p21WAF1/CIP1:
Forward: 5'-CCACTGGAGGGTGACTTCG-3'
Reverse: 5'-TGCAGCAGAGCAGGTGAGG-3'
RXRα shRNA
The lentiviral vector-based shRNA technique was used to knockdown endogenous RXRα in 
KM12C cells. The targeted sequences of human RXRα shRNA was 5′-
GTGTTGTCACCCTCCTTATTT-3′; 5′-CCTGTCTGGAGTGACATCT -3′. The negative control 
shRNA sequence was 5′-GGCTACGTCCAGGAGCGCACC-3′. 
Mouse xenograft models
Male six-week-old nude mice (BALB/c, SPF grade, 19-23 g) were maintained in Xiamen 
University Experimental Animal Center. The mice were allowed to get accustomed to the new 
environment for one week before the experiment. All animal studies were handled in accordance 
with the Institutional Animal Use and Care Committee of Xiamen University (China). KM12C 
cells (1×106 per mouse) resuspended in 100 μL Hank's Balanced Salt Solution (HBSS) were 
subcutaneously injected into both flanks of nude mice. The tumor-bearing mice were randomly 
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divided into three groups after seven days and were then treated daily with Vehicle 
(Carboxymethyl Cellulose Sodium-Na, CMC-Na), berberine (100 mg/kg body weight), and B-12 
(100 mg/kg body weight) by intragastric administration daily for 15 days. Then the mice were 
euthanized and the tumors were removed for follow-up study. 
Determination of Serum biochemical indexes
Serum samples were collected from mice and the following biochemical indexes were 
measured: liver function indexes (Bilirubin total (TBIL), indirect Bilirubin (IBIL), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP); 
kidney function indexes (urea formaldehyde (UREA), and creatinine (CREA)); glycolipid function 
indexes (total cholesterol (TC), and triglyceride (TG)); and Calcium (Ca) concentration. All the 
indexes were measured by using Automatic Chemistry Analyzer（BS-240vet, Mindray Bio-
Medical Electronics Co., Ltd. Shenzhen, China).
Immunohistochemical assay 
Tumor tissue specimens were fixed with neutral formalin and embedded in paraffin. Tissue 
sections (4 μm thick) were dewaxed and deparaffinized in xylene, followed by treatment with a 
graded series of alcohol (100, 95, 85, and 70%) and rehydration in PBS (pH 7.5). After that, tissue 
sections were immersed in 3% hydrogen peroxide for 10 min to suppress endogenous peroxidase 
activity, and then successively incubated with 0.01 M natrium citricum (pH 6.0) for antigen 
retrieval. The slides were rinsed in PBS (pH 7.5) and incubated with diluted antibody incubating 
at 4 °C overnight and performed with the immunostaining kit according to the manufacturer’s 
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instructions. DAB Detection Kit (cat. #Kit-0014) was purchased from Maixin Biotech (Fuzhou, 
China).
Pharmacokinetics Study
SD rats weighed 200  20 g were housed at 28 °C in a laminar flow under sterilized conditions. 
Rats were randomly divided into three groups and then treated with berberine (100 mg/kg), B-12 
(100 mg/kg) or vehicle (0.5% CMC-Na) by intragastric administration. Blood samples (0.5 mL) 
were collected via the tail vein at 0.083、0.25、0.5、1、2、4、8、12、24、36 h after 
intragastric administration. After centrifugation at 2000 rpm for 10 min, the resulting plasma was 
frozen at -80 °C until LC-MS/MS quantification. Pharmacokinetic data analyses were conducted 
using a noncompartmental analysis model (DAS 2.0, T.C.M., Shanghai, China). All animal 
procedures were approved by the Animal Care and Use Committee of Xiamen University.
Solubility measurements
The gravimetric method was used to detect the solubility of berberine and its analogues. In brief, 
excess amount of powder was added into 10 mL deionized water in three parallel groups for each 
compound. Samples were shaken at 37 °C for 24 h, and centrifuged at 10,000 rpm for 5 min. Then 
5 mL supernatant was taken out and put into an evaporating dish (dried and weighed in advance, 
whose net weight was labeled as W1 (with the unit of grams), which was subsequently placed in 
the oven at 60 °C until the weight became constant. The total mass of the compound and the 
evaporating dish was then weighed (in the accuracy of 0.0001 g) and labeled as W2 (with the unit 
of grams).  The solubility of berberine and berberine analogues in water (mg/mL) is calculated 
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according to the following formula: X = (W2-W1)/5×103, in which 5 is the volume of the 
supernatant (mL).  
Statistical analyses
All results are shown as mean ± SEM. Statistical significance is analyzed by one-way or two-
way ANOVA by GraphPad Prism software (version 5.0, GraphPad Software Inc., La Jolla, CA, 
USA). The statistical significance was expressed as *p < 0.05, **p < 0.01 and ***p< 0.001.
■ ABBREVIATIONS
Retinoid X receptor α (RXRα); structure-activity analysis (SAR); adenomatous polyposis coli 
(APC); ligand-binding pocket (LBP); ligand-binding domian (LBD); 9-cis-retinoid acid (9-cis-
RA); berberine (Ber); hydrogen bonds (H-bonds); 5-Ethynyl-2’-deoxyuridine (EdU); proliferating 
cell nuclear antigen (PCNA); saturation transfer difference (STD); nuclear magnetic resonance 
(NMR); far-ultraviolet circular dichroism spectrum (far-UV CD spectrum); area under the curve 
(AUC)
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